XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition
 3 Months Ended
Mar. 31, 2022
Revenue Recognition [Abstract]  
Revenue Recognition REVENUE RECOGNITION
Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2021.
We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.
Net Sales by Product Line
Three Months
20222021
MedSurg and Neurotechnology:
Instruments$528 $469 
Endoscopy538 469 
Medical664 622 
Neurovascular301 289 
Neuro Cranial323 281 
Other69 61 
$2,423 $2,191 
Orthopaedics and Spine:
Knees$464 $412 
Hips327 309 
Trauma and Extremities685 640 
Spine279 278 
Other97 123 
$1,852 $1,762 
Total$4,275 $3,953 
Net Sales by Geography
Three Months 2022Three Months 2021
United StatesInternationalUnited StatesInternational
MedSurg and Neurotechnology:
Instruments$414 $114 $355 $114 
Endoscopy418 120 354 115 
Medical525 139 473 149 
Neurovascular110 191 111 178 
Neuro Cranial264 59 224 57 
Other68 1 60 1 
$1,799 $624 $1,577 $614 
Orthopaedics and Spine:
Knees$345 $119 $294 $118 
Hips202 125 186 123 
Trauma and Extremities487 198 440 200 
Spine200 79 193 85 
Other72 25 94 29 
$1,306 $546 $1,207 $555 
Total$3,105 $1,170 $2,784 $1,169 
Contract Assets and Liabilities
On March 31, 2022 and December 31, 2021 contract assets recorded in our Consolidated Balance Sheets were not significant.
Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $635 and $529 on March 31, 2022 and December 31, 2021.